EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

Hana Dostálová, Vladimír Kryštof iD

Hematological Oncology · 2024

DOI: 10.1002/hon.3294 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2024. Verfasst von Hana Dostálová und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Drug Resistance, Neoplasm, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Palackého v Olomouci, Grantová Agentura České Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B‐cell malignancies. They target BTK, a key effector in the B‐cell receptor (BCR) signaling pathway, crucial for B‐cell survival and proliferation. The first‐in‐class irreversible BTK inhibitor, ibrutinib, was approved for various B‐cell malignancies but has limitations due to off‐target effects. Second‐generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects. However, resistance to BTK inhibitors, driven by BTK mutations, remains a challenge. Combinatorial therapies with PI3K inhibitors, immune checkpoint inhibitors, BH3 mimetics, and anti‐CD20 antibodies show promise in overcoming resistance. Noncovalent BTK inhibitors and proteolysis‐targeting chimeras (PROTACs) are emerging strategies with potential to combat resistance. Overall, advancements in BTK‐targeted therapies provide hope for improved outcomes in patients with B‐cell malignancies and a promising avenue to address drug resistance. Further research is needed to optimize combination therapies and identify optimal treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseDrug Resistance, NeoplasmPyrazolesPyrimidinesProtein Kinase InhibitorsPiperidinesHumansLymphoma, B-CellTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

BTKinhibitorresistancezanubrutinib

Substanzen

Agammaglobulinaemia Tyrosine KinasezanubrutinibPyrazolesPyrimidinesProtein Kinase InhibitorsPiperidinesBTK protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic.

ORCID-Profile: Vladimír Kryštof

Förderung

  • Univerzita Palackého v Olomouci
  • Grantová Agentura České Republiky

Zitieren

APA

Dostálová, H., & Kryštof, V. (2024). Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological Oncology. https://doi.org/10.1002/hon.3294

Vancouver

Dostálová H, Kryštof V. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological Oncology. 2024. doi:10.1002/hon.3294

BibTeX
@article{Dostlov2024,
  author = {Dostálová, Hana and Kryštof, Vladimír},
  title = {Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3294}
}
Kostenlos starten →